VEGFA and diabetes mellitus: Treatment of diabetic rodents with arange of agents that either modulate protein kinase C activation [13], prevent formation of reactive oxygen species (ROS)[14], or regulate aldose reductase activity [15, 16] canprevent diabetes-mediated rises in VEGF expression and prevent iBRB dysfunction.